Preprint Effect of Immunoadsorption on clinical presentation and immune alterations in COVID-19-associated ME/CFS, 2024, Anft

Effect of Immunoadsorption on clinical presentation and immune alterations in COVID-19-associated ME/CFS

Moritz Anft, Lea Wiemers, Kamil Rosiewicz, Adrian Doevelaar, Sarah Skrzypczyk, Julia Kurek, Sviatlana Kaliszczyk, Maximilian Seidel, Ulrik Stervbo, Felix S. Seibert, Timm H. Westhoff, Nina Babel

doi: https://doi.org/10.1101/2024.09.25.24314345

https://www.medrxiv.org/content/10.1101/2024.09.25.24314345v1

Abstract

Autoreactive antibodies (AAB) are currently being investigated as causative or aggravating factors during post-COVID.

In this study we analyze the effect of immunoadsorption therapy on symptom improvement and the relationship with immunological parameters in post-COVID patients exhibiting symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

This observational study includes 12 post-COVID patients exhibiting a predominance of ME/CFS symptoms alongside increased concentrations of autonomic nervous system receptors (ANSR) autoantibodies and neurological impairments.

We found that following immunoadsorption therapy, the ANSR autoantibodies were nearly eliminated from the patients' blood.

The removal of IgG antibodies was accompanied by a decrease of pro-inflammatory cytokines including IL4, IL2, IL1β, TNF and IL17A serum levels, and a significant reduction of soluble spike protein.

Notably, a strong positive correlation between pro-inflammatory cytokines and ASNR-AABs β1, β2, M3, and M4 was observed in spike protein-positive patients, whereas no such correlation was evident in spike protein-negative patients. 30 days post-immunoadsorption therapy, patients exhibited notable improvement in neuropsychological function and a substantial amelioration of hand grip strength was observed.

However, neither self-reported symptoms nor scores on ME/CSF questionnaires showed a significant improvement and a rebound of the removed proteins occurring within a month.